Comments
New Delhi, December 11 Cadila Healthcare arm has received approval from the US health regulator to market Ranitidine injection, used to treat stomach and duodenal (intestinal) ulcers.
Liva Pharmaceuticals, a wholly-owned subsidiary of Cadila Healthcare, has received approval from the US Food and Drug Administration (USFDA) for its supplemental abbreviated new drug application, Ranitidine Injection USP, 25 mg/mL, 2 mL single dose vials and 6 mL multi-dose vials, Cadila Healthcare said in a BSE filing today.
Cadila Healthcare said the product will be manufactured at Liva Pharma’s manufacturing facility at Vadodara, and is the first product to be approved from this site for marketing in the US. The company has more than 237 approvals, and has so far filed over 340 abbreviated new drug applications (ANDAs) since it had commenced filings in 2003-04.
Shares of Cadila Healthcare were trading 1.22 per cent higher at Rs 345.20 apiece on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.